Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Lasa Supergenerics Ltd

    Lasa Supergenerics Ltd is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain?from discovery-to-delivery, with established cred

  • No Image
    Lifespan Biotech Pvt Ltd

    Lifespan Biotech Private Limited was incorporated on 18th August 2005 at Bhopal, Madhya Pradesh for the manufacture of injectables to cater to the needs of pharmaceutical compan

  • No Image
    Lincoln Pharmaceuticals Ltd

    Established as a partnership firm in 1979, Lincoln Pharmaceuticals Ltd has been engaged in manufacturing and trading of pharmaceutical formulations in the domestic market as wel